YOLFTbeta
Innovent Biologics Inc

Innovent Biologics Inc

6IB · F · Healthcare / Biotechnology

9.68EUR-0.20 (-2.06%)

Price History

Full chart

Market Stats

Previous Close9.88
Open9.63
Day Range9.63 – 9.68
52-Week Range7.91 – 12.10
Volume0
Market Cap18.82B
P/E (TTM)119.91
Forward P/E46.30
EPS0.09
Dividend Yield0.00%
Beta0.24
50-Day Avg10.62
200-Day Avg9.52

About

Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, Europe, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), PEMAZYRE (pemigatinib), olverembatinib, Cyramza (ramucirumab), Retsevmo (selpercatinib), FUCASO (Equecabtagene Autoleucel), SINTBILO (tafolecimab injection), DUPERT (fulzerasib), DOVBLERON (taletrectinib adipate), Jaypirca (pirtobrutinib), limertinib, SYCUME (teprotumumab N01 injection), mazdutide, PECONDLE (picankibart injection), and TABOSUN(Ipilimumab N01 injection). In addition, it sells and distributes pharmaceutical products; and offers consultation and research and development services. The company was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. De-Chao Yu Ph.D.
  • Employees8.75K
  • Headquarters168 Dongping Street, Suzhou, China, 215123, Germany
  • Websitehttps://www.innoventbio.com

Leadership

  • Dr. De-Chao Yu Ph.D.Co-Founder, Chairman & CEO · b. 1964
  • Mr. Hao Xi EdeNon-Executive Director & Fund Managing Partner · b. 1959
  • Ms. Qian ZhangChief Commercial Officer, General Manager & Executive Director · b. 1987
  • Ms. Fei You CPAChief Financial Officer · b. 1979
  • Dr. Kaisong Zhou Ph.D.Chief Operating Officer
  • Ms. Zhengwei Song C.F.A.Director of IR & Financial Strategy
  • Ms. Cong Ding J.D.General Counsel
  • Mr. Blake SalisburySenior Vice President
  • Dr. Hui Zhou Ph.D.Chief R&D Officer for Oncology
  • Dr. Samuel Suhua Zhang M.B.A., Ph.D.Global Chief Business Officer · b. 1968

Financials

Income Statement

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue018.54M9.48M1.05B3.84B4.27B4.56B6.21B9.42B13.04B
Growth (%)---48.88%+10953.34%+266.94%+11.08%+6.71%+36.21%+51.82%+38.42%
Cost of Revenue---124.88M387.76M573.04M930.99M1.14B1.51B1.76B
Gross Profit---922.65M3.46B3.70B3.63B5.07B7.91B11.29B
Gross Margin---88.08%89.91%86.58%79.57%81.69%83.97%86.54%
Operating Expense---2.70B3.63B6.09B6.21B5.98B7.65B9.14B
Operating Income-413.27M-624.73M-1.55B-1.78B-173.13M-2.39B-2.58B-909.21M258.12M2.14B
Operating Margin--3369.99%-16382.83%-169.76%-4.50%-56.06%-56.67%-14.65%2.74%16.42%
EBITDA--597.72M-5.74B-1.57B-790.36M-2.99B-1.75B-660.68M408.79M1.52B
EBITDA Margin--3224.32%-60567.17%-150.27%-20.56%-69.99%-38.39%-10.65%4.34%11.65%
Net Income-504.20M-562.32M-5.77B-1.72B-998.42M-3.14B-2.18B-1.03B-94.63M813.57M
Net Income Margin--3033.33%-60899.99%-164.19%-25.97%-73.50%-47.83%-16.56%-1.00%6.24%
R&D384.65M611.92M1.22B1.29B1.85B2.48B2.87B2.23B2.68B2.62B
R&D as % of Total Revenue-3300.91%12891.07%123.60%48.17%58.04%63.02%35.89%28.46%20.12%
Interest Expense0068.97M59.49M68.35M62.46M101.70M98.62M67.65M79.60M
Interest Expense % of Total Revenue-0.00%727.75%5.68%1.78%1.46%2.23%1.59%0.72%0.61%

Balance Sheet

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets2.82B2.46B6.11B7.23B11.83B16.24B17.59B20.63B21.60B37.35B
Total Liabilities3.77B4.08B1.92B2.47B3.06B5.91B6.86B8.10B8.48B17.99B
Total Equity-1.38B-1.94B4.19B4.76B8.78B10.33B10.73B12.53B13.12B19.36B
Cash1.01B510.47M4.53B2.43B7.76B8.38B1.02B2.75B7.51B17.34B
Net Debt-----1.03B2.09B776.24M--

Cash Flow

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-362.99M-492.27M-1.01B-1.66B-307.69M-2.02B-1.92B147.81M1.29B10.00B
Investing Cash Flow-572.08M-349.46M855.23M-2.57B-5.18B-2.70B----
Financing Cash Flow-89.41M4.43B2.11B4.91B5.00B----
Capital Expenditure58.44M90.97M312.74M365.87M489.02M1.07B1.38B1.38B1.71B683.27M
Free Cash Flow--583.24M-1.33B-2.03B-1.08B-3.87B-3.30B-1.24B-418.39M9.32B
FCF to OCF-118.48%131.32%121.98%350.83%191.24%172.01%-835.97%-32.51%93.17%

Earnings

Report DateMar 25, 2027
EPS Estimate-
EPS Actual-
Surprise-
TimingAfter-hours

Key Statistics & Ratios

Market Cap18.82B
Enterprise Value18.07B
Trailing P/E119.91
Forward P/E46.30
PEG Ratio0.96
Price / Sales1.20
Price / Book7.84
EPS0.09
Book Value1.58
Revenue (TTM)15.71B
Gross Profit (TTM)12.02B
EBITDA1.80B
Profit Margin7.85%
Operating Margin13.99%
Return on Equity7.01%
Return on Assets2.23%
Shares Outstanding1.74B
Shares Float1.61B
Beta0.24
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%